


QR-0217

Cat. No.:	HY-153416		
CAS No.:	1027786-12-4		
Molecular Formula:	C ₁₉ H ₁₃ NO ₃		
Molecular Weight:	303.31		
Target:	Amyloid- β		
Pathway:	Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (329.70 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.2970 mL	16.4848 mL	32.9696 mL
		5 mM	0.6594 mL	3.2970 mL	6.5939 mL
10 mM		0.3297 mL	1.6485 mL	3.2970 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (8.24 mM); Clear solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: 2.5 mg/mL (8.24 mM); Clear solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	QR-0217 is a potent A β 1-40 aggregation inhibitor with an IC ₅₀ value of 7.5 μ M. QR-0217 inhibits α -synuclein aggregation. QR-0217 reduces memory impairments caused by A β neurotoxicity ^[1] .
IC₅₀ & Target	IC ₅₀ : 7.5 μ M (A β 1-40) ^[1]
In Vitro	QR-0217 (20, 100 μ M; 96 h) inhibits α -synuclein (4 μ M) aggregation ^[1] . QR-0217 (50 μ M) significantly rescues impairment of LTP in the APP/PS1 transgenic mice hippocampal slices ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Michael D. Carter, et al. Compounds and methods for treating protein folding disorders. US8362066B2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA